Li CG, Zhou ZP, Jia YZ, Tan XL, Song YY. Radioactive 125I seed implantation for pancreatic cancer with unexpected liver metastasis: A preliminary experience with 26 patients. World J Clin Cases 2021; 9(4): 792-800 [PMID: 33585625 DOI: 10.12998/wjcc.v9.i4.792]
Corresponding Author of This Article
Cheng-Gang Li, MD, PhD, Associate Professor, Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. lcgang301@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 6, 2021; 9(4): 792-800 Published online Feb 6, 2021. doi: 10.12998/wjcc.v9.i4.792
Radioactive 125I seed implantation for pancreatic cancer with unexpected liver metastasis: A preliminary experience with 26 patients
Cheng-Gang Li, Zhi-Peng Zhou, Yu-Ze Jia, Xiang-Long Tan, Yu-Yao Song
Cheng-Gang Li, Zhi-Peng Zhou, Yu-Ze Jia, Xiang-Long Tan, Yu-Yao Song, Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Li CG and Zhou ZP contributed equally to this work and should be considered as co-first authors; Li CG, Zhou ZP, and Jia YZ analyzed and interpreted the data and wrote the article; Jia YZ, Tan XL, and Song YY drafted the work and collected the data; Li CG designed the study and revised the article for important intellectual content.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Chinese PLA General Hospital (No. S2016-098-02).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors declare no conflicts of interest related to this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cheng-Gang Li, MD, PhD, Associate Professor, Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. lcgang301@126.com
Received: November 16, 2020 Peer-review started: November 16, 2020 First decision: November 29, 2020 Revised: December 3, 2020 Accepted: December 11, 2020 Article in press: December 11, 2020 Published online: February 6, 2021
ARTICLE HIGHLIGHTS
Research background
The liver is the most common target organ for metastasis of pancreatic cancer. The survival time of pancreatic cancer patients with liver metastasis is very short, and they need timely and effective treatment.
Research motivation
There is no consensus on the treatment strategy for patients with pancreatic cancer and liver metastasis.
Research objectives
To evaluate the therapeutic effect of radioactive 125I seed implantation for pancreatic cancer patients with unexpected liver metastasis.
Research methods
The demographics and perioperative outcomes of patients who underwent 125I seed implantation to treat pancreatic cancer with unexpected liver metastasis were retrospectively analyzed.
Research results
There was a significant difference in the 1-year survival rate between the chemotherapy group and non-chemotherapy group. The mean overall survival of patients in the chemotherapy group was 16.3 mo, while it was 10 mo in the non-chemotherapy group.
Research conclusions
The survival time of pancreatic cancer patients with unexpected liver metastasis could be prolonged, and their quality of life could be improved by 125I seed implantation combined with postoperative chemotherapy.
Research perspectives
With the development of science and technology, the cure rate of cancer will be higher and higher.
